[Effect of etretinate treatment on fluidity and lipid composition of the erythrocyte membrane in patients with psoriasis].
The effect of etretinate (Ro 10-9359) treatment, at low daily dose (0.3 mg/kg), on erythrocyte membrane and physico-chemical state in psoriatic patients has been studied. The results have shown that etretinate induces a significant increase of erythrocyte membrane fluidity, as shown by a decrease of fluorescence polarization. In fact the values of 1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence polarization were significantly decreased after therapy in comparison with the values observed at the beginning of the study. The modifications of membrane fluidity were associated with modifications of lipid composition. In fact the study of membrane composition has revealed a decrease of the cholesterol to protein ratio and slight but not significant changes of phospholipid fatty acid composition.
Simonetti
O
O
Messini
L
L
D000328:Adult; D004910:Erythrocyte Membrane / Q000187:drug effects*; D005050:Etretinate / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects*; D008563:Membrane Lipids / Q000032:analysis*; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy
D008055:Lipids; D008563:Membrane Lipids; D005050:Etretinate
Effetto del trattamento con etretinato sulla fluidità e composizione lipidica della membrana eritrocitaria in pazienti con psoriasi.